References
- Légifrance. Loi no. 75–17 du 17 janvier 1975 relative à l’interruption volontaire de la grossesse. Available from: www.legifrance.gouv.fr/affichTexte.do?cidTexte=JORFTEXT000000700230 (Accessed 5 August 2018).
- Ministère des Solidarités et de la Santé. Les interruptions volontaires de grossesse en 2013; 2015. Available from: https://drees.solidarites-sante.gouv.fr/etudes-et-statistiques/publications/etudes-et-resultats/article/les-interruptions-volontaires-de-grossesse-en-2013 (Accessed 5 August 2018).
- Agostini A, Vayssière C. Induced abortion: guidelines for clinical practice: introduction [article in French]. J Gynecol Obstet Biol Reprod (Paris). 2016;45:1458.
- Kahn JG, Becker BJ, MacIsaa L, et al. The efficacy of medical abortion: a meta-analysis. Contraception. 2000;61:29–40.
- Spitz IM, Bardin CW, Benton L, et al. Early pregnancy termination with mifepristone and misoprostol in the United States. N Engl J Med. 1998;338:1241–1247.
- Pallavee P, Samal R, Begum J, et al. Foetal fibular hemimelia with focal femoral deficiency following prenatal misoprostol use: a case report. J Obstet Gynaecol. 2016;36:760–761.
- Bettahar K, Pinton A, Boisramé T, et al. Interruption volontaire de grossesse par voie médicamenteuse. J Gynecol Obstet Biol Reprod (Paris). 2016;45:1490–1514.
- Raymond EG, Shochet T, Blum J, et al. Serial multilevel urine pregnancy testing to assess medical abortion outcome: a meta-analysis. Contraception. 2017;95:442–448.
- Rossi B, Creinin MD, Meyn LA. Ability of the clinician and patient to predict the outcome of mifepristone and misoprostol medical abortion. Contraception. 2004;70:313–317.
- Harwood B, Meckstroth KR, Mishell DR, et al. Serum beta-human chorionic gonadotropin levels and endometrial thickness after medical abortion. Contraception 2001;63:255–256.
- Tzeng C-R, Hwang J-L, Au H-K, et al. Sonographic patterns of the endometrium in assessment of medical abortion outcomes. Contraception 2013;88:153–159.
- Reeves MF, Fox MC, Lohr PA, et al. Endometrial thickness following medical abortion is not predictive of subsequent surgical intervention. Ultrasound Obstet Gynecol. 2009;34:104–109.
- Fiala C, Safar P, Bygdeman M, et al. Verifying the effectiveness of medical abortion; ultrasound versus hCG testing. Eur J Obstet Gynecol Reprod Biol. 2003;109:190–195.
- Collège National des Gynécologues Obstétriciens Français. Recommandations pour la pratique clinique. L’interruption volontaire de grossesse; 2016. Available from: www.cngof.fr/pratiques-cliniques/recommandations-pour-la-pratique-clinique/apercu?path=RPC%2BCOLLEGE%252FRPC_2016_IVG.pdf&i=7804 (Accessed 5 August 2018).
- Clark W, Bracken H, Tanenhaus J, et al. Alternatives to a routine follow-up visit for early medical abortion. Obstet Gynecol. 2010;115:264–272.
- Blanchard K, Winikoff B, Ellertson C. Use of misoprostol during pregnancy and Möbius' syndrome in infants. N Engl J Med. 1998;339:1553–1554.
- Walker K, Schaff E, Fielding S, et al. Monitoring serum chorionic gonadotropin levels after mifepristone abortion. Contraception 2001;64:271–273.
- Honkanen H, Ranta S, Ylikorkala O, et al. The kinetics of serum hCG and progesterone in response to oral and vaginal administration of misoprostol during medical termination of early pregnancy. Hum Reprod. 2002;17:2315–2319.
- Jackson AV, Dayananda I, Fortin JM, et al. Can women accurately assess the outcome of medical abortion based on symptoms alone? Contraception 2012;85:192–197.
- Wiegerinck MMJ, Jones HE, O'Connell K, et al. Medical abortion practices: a survey of National Abortion Federation members in the United States. Contraception 2008;78:486–491.
- Rossi AC, Prefumo F. Accuracy of ultrasonography at 11–14 weeks of gestation for detection of fetal structural anomalies: a systematic review. Obstet Gynecol. 2013;122:1160–1167.
- Creinin MD. Change in serum beta-human chorionic gonadotropin after abortion with methotrexate and misoprostol. Am J Obstet Gynecol. 1996;174:776–778.
- Thonneau P, Fougeyrollas B, Spira A. Analysis of 369 abortions conducted by mifepristone (RU486) associated with sulprostone in a French family planning center. Fertil Steril. 1994;61:627–631.
- Pocius KD, Maurer R, Fortin J, et al. Early serum human chorionic gonadotropin (hCG) trends after medication abortion. Contraception 2015;91:503–506.
- Cameron ST, Glasier A, Johnstone A, et al. Can women determine the success of early medical termination of pregnancy themselves?. Contraception 2015;91:6–11.
- Oppegaard KS, Qvigstad E, Fiala C, et al. Clinical follow-up compared with self-assessment of outcome after medical abortion: a multicentre, non-inferiority, randomised, controlled trial. Lancet 2015;385:698–704.
- Michie L, Cameron ST. Simplified follow-up after early medical abortion: 12-month experience of a telephone call and self-performed low-sensitivity urine pregnancy test. Contraception 2014;89:440–445.
- Hassoun D, Périn I, Hiên H, et al. Feasibility of self-performed urine pregnancy testing for follow-up after medical abortion. Eur J Obstet Gynecol Reprod Biol. 2016;197:174–178.
- Reeves MF, Monmaney JA, Creinin MD. Predictors of uterine evacuation following early medical abortion with mifepristone and misoprostol. Contraception 2016;93:119–125.
- World Health Organization. Safe abortion: technical and policy guidance for health systems. 2nd ed. Geneva: WHO; 2012.